Saturday 17 October 2026
Export VAXX’s income statement to Excel — free account
Vaxxinity, Inc.
VAXX Healthcare Biotechnology
0.00
0.00
NaN
Follow VAXX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 5.26 | 1.24 | 0.69 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | 22.77 | 10.57 | 4.47 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 75 | 89 | 89 | 65 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 0 | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 90.66 | (2,834.85) | 0.00 | — | |||||
| EBT | — | — | — | — | — | (14) | (40) | (137) | (75) | (57) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | (7,173.61) | (207,840.91) | 0.00 | 0.00 | |||||
| Net income | — | — | — | 0 | — | (14) | (40) | (137) | (75) | (57) | |||||
| Depreciation | — | — | — | — | — | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | (0.42) | (0.61) | (1.79) | (0.60) | (0.45) | |||||
| Cash flow | — | — | — | — | — | (0.36) | (0.52) | (1.06) | (0.44) | (0.45) | |||||
| Capex | — | — | — | — | — | 0.00 | (0.02) | (0.02) | (0.01) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | (0.36) | (0.54) | (1.07) | (0.46) | (0.46) | |||||
| Book value | — | — | — | — | — | (1.42) | (1.33) | 1.68 | 0.49 | 0.11 | |||||
| Shares, m | — | — | — | — | — | 34 | 66 | 77 | 126 | 127 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | — | ||||
| P/S | — | — | — | — | — | — | 1,822.86 | 2,347.83 | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | 3.34 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 1,696.24 | 1,611.58 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | (13.26) | (3.56) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (12) | (34) | (81) | (56) | (57) | ||||
| Capex | — | — | — | — | — | — | (1) | (1) | (2) | (1) | |||||
| Free cash flow | — | — | — | — | — | (12) | (35) | (82) | (58) | (58) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (18) | (4) | 127 | 63 | 16 | ||||
| Total debt | — | — | — | — | — | 1 | 11 | 10 | 13 | 13 | |||||
| Net debt | — | — | — | — | — | 1 | (20) | (135) | (75) | (17) | |||||
| Shareholders’ equity | — | — | — | — | — | (49) | (87) | 129 | 62 | 13 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (1,782.95) | (154.46) | (126.54) | (55.09) | (75.55) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 20.93 | 58.81 | (665.19) | (78.85) | (150.65) | |||||
Negative figures in brackets.
Fiscal years to Dec 2021 · latest quarter Dec 2021
Charts ten years each
Vaxxinity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBM Psyence Biomedical Ltd. | $16.5M | 0.2× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRX TScan Therapeutics, Inc. | $16.2M | — (loss-making) | — (loss-making) | −65.83% (below 0%: shrinking) | n/m | +18.95% (above 0%: growing) | 100.00% | (2,901.33%) | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | |
| AKTX Akari Therapeutics PLC | $15.5M | — (loss-making) | — | — | n/m | +4.51% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $15.3M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | −97.84% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.3M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| GTBP GT Biopharma, Inc. | $15.2M | — (loss-making) | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DARE Dare Bioscience, Inc. | $14.6M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| Median of peers | $15.3M | — | — | −65.83% | — | −64.52% | 0.00% | 0.00% |
Vaxxinity, Inc. (VAXX) Latest News
No news at this impact. Lower the threshold for more.